Alaunos Therapeutics Inc
$ 3.56
8.54%
03 Dec - close price
- Market Cap 7,945,300 USD
- Current Price $ 3.56
- High / Low $ 3.64 / 3.19
- Stock P/E N/A
- Book Value 1.27
- EPS -2.30
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.70 %
- ROE -1.46 %
- 52 Week High 5.48
- 52 Week Low 1.31
About
Alaunos Therapeutics Inc. is a clinical-stage biopharmaceutical company based in Houston, Texas, specializing in the development of groundbreaking immuno-oncology therapies aimed at treating cancer. The company leverages its proprietary T Cell Receptor (TCR) therapy platform to design more effective, targeted treatments for patients with solid tumors, representing a novel approach in the ongoing battle against cancer. With its advancements in clinical trials, Alaunos is well-positioned to significantly impact the oncology landscape, potentially delivering new treatment options that offer renewed hope for patients with historically challenging diagnoses.
Analyst Target Price
$1.75
Quarterly Earnings
| Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-08-14 | 2025-05-13 | 2025-03-31 | 2024-11-12 | 2024-08-14 | 2024-04-01 | 2024-03-05 | 2023-11-14 | 2023-08-14 | 2023-05-10 | 2023-03-07 | 2022-11-14 |
| Reported EPS | -0.63 | -0.6701 | -0.4634 | -0.7038 | -0.7051 | -0.49 | -0.49 | -0.04 | -0.04 | -0.04 | -0.04 | -0.04 |
| Estimated EPS | None | None | None | None | None | -0.45 | -0.45 | -0.04 | -0.04 | -0.04 | -0.07 | -0.08 |
| Surprise | 0 | 0 | 0 | 0 | 0 | -0.04 | -0.04 | 0 | 0 | 0 | 0.03 | 0.04 |
| Surprise Percentage | None% | None% | None% | None% | None% | -8.8889% | -8.8889% | 0% | 0% | 0% | 42.8571% | 50% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TCRT
2025-10-22 11:31:49
PMGC Capital LLC, a subsidiary of PMGC Holdings Inc. (ELAB), announced its intention to file a Schedule 13D, disclosing a 5.09% beneficial ownership stake in Alaunos Therapeutics, Inc. (TCRT). PMGC Capital acquired 83,500 shares of Alaunos Therapeutics, driven by a belief that the company is undervalued and holds significant potential for shareholder value creation. PMGC Capital plans to engage with Alaunos' management and board to explore strategic opportunities, including potential mergers, acquisitions, or partnerships, particularly in financial technology and cryptocurrency sectors.
2025-10-22 11:31:49
Alaunos Therapeutics Inc. (TCRT) has shifted its strategic focus to an internally developed small molecule oral obesity program, ceasing development of its TCR-T clinical programs due to high costs. The company reported a net loss of $4.6 million for the year ended December 31, 2024, and faces substantial doubt about its ability to continue as a going concern without additional financing. Alaunos is exploring strategic alternatives while its stock remains listed on Nasdaq.
2025-10-15 06:51:47
Alaunos Therapeutics (NASDAQ:TCRT) has received a "Sell (D-)" rating from Weiss Ratings. The clinical-stage oncology company specializes in developing adoptive T-cell receptor engineered T-cell therapies (TCR-T) to treat various solid tumor types. The report comes as shares of Alaunos Therapeutics have recently increased by 5.5%.
2024-11-14 00:00:00
Alaunos Therapeutics Inc. filed its 10-Q report for the quarter ended September 30, 2024, detailing strategic reprioritization, workforce reduction, and exploration of strategic alternatives. The company reported a significant decrease in cash to $1.7 million and an accumulated deficit of $919.7 million, alongside no revenue and a net loss of $1.1 million for the quarter. Alaunos is also evaluating its obesity program and is under a Nasdaq panel monitor, having terminated key license agreements.
2023-04-26 12:30:00
Alaunos Therapeutics, Inc. (TCRT) announced a poster presentation for its lead Sleeping Beauty TCR-T cell therapy program at the 2023 ASCO Annual Meeting, scheduled for June 2-6, 2023, in Chicago. The presentation will detail safety and efficacy from its Phase 1/2 trial focusing on solid tumors with specific KRAS and TP53 driver mutations. Maria Pia Morelli, M.D., Ph.D. from MD Anderson, will present the findings on June 3.
2022-05-10 18:46:57
Alaunos Therapeutics, Inc. announced that its CEO, Kevin S. Boyle Sr., and VP of Research & Development, Drew Deniger, Ph.D., will present at the H.C. Wainwright Global Investment Conference. The conference is scheduled to be held from May 23-26, 2022, in Miami Beach, FL. Alaunos Therapeutics (Nasdaq: TCRT) is a clinical-stage oncology-focused cell therapy company.
